Siltuximab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Siltuximab: From Multicentric Castleman Disease to Extracutaneous Mastocytoma
One-Sentence Summary
Siltuximab is an anti-interleukin-6 (IL-6) monoclonal antibody approved for multicentric Castleman disease (MCD). The TxGNN model predicts it may be effective for Extracutaneous Mastocytoma, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multicentric Castleman Disease (MCD) — referenced in evidence pack rationale text; not present in formal license data |
| Predicted New Indication | Extracutaneous Mastocytoma |
| TxGNN Prediction Score | 99.64% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not formally recorded for Siltuximab in this evidence pack (drug-level MOA field is a data gap). However, supporting trial documentation elsewhere in the pack describes Siltuximab as a recombinant chimeric (human-murine) anti-IL-6 monoclonal antibody, administered by intravenous infusion, and notes it is approved for multicentric Castleman disease — a lymphoproliferative disorder driven in part by IL-6 signalling.
For the top-ranked predicted indication, extracutaneous mastocytoma, the evidence pack’s own mechanistic assessment is explicitly skeptical: mastocytoma pathology is driven primarily by KIT mutations and mast cell proliferation, a pathway with only weak, unsubstantiated overlap with IL-6 inhibition. No clinical or literature evidence accompanies this prediction — it is a high TxGNN score without independent corroboration.
By contrast, other candidates further down the same prediction list — notably Kaposi’s sarcoma (rank 9–10, score 99.28%) — have a more coherent mechanistic story (shared HHV-8/KSHV viral driver with MCD, IL-6 implicated in tumor microenvironment) and at least one supporting literature reference, though still no direct clinical evidence. This suggests the overall repurposing signal for Siltuximab is stronger for virally-driven, IL-6-associated conditions than for the top-ranked mastocytoma prediction itself.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Siltuximab currently holds no marketing authorisation in Denmark (0 registered products; market status: not marketed).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Note: label-level warnings/contraindications and a formal DDI screen for Siltuximab are flagged as outstanding, blocking data gaps in this evidence pack (no source could yet be queried for warnings, contraindications, or drug interactions).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (extracutaneous mastocytoma) has no clinical trial or literature support and a mechanistic link the evidence pack itself describes as weak — this is a pure L5 model score, insufficient to advance.
To proceed, the following is needed:
- Formal mechanism-of-action documentation for Siltuximab (currently a data gap)
- Danish/EU label warnings and contraindications (blocking gap — required before any S1 safety screen)
- A completed drug-interaction query (current status: not found)
- Independent preclinical or mechanistic rationale connecting IL-6 inhibition to mast cell tumor biology before pursuing mastocytoma further
- If pursuing the IL-6/viral-driven signal instead, prioritize the Kaposi’s sarcoma candidate (L4, Research Question stage) for deeper literature review, since it currently has the pack’s only literature support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.